Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells (Articolo in rivista)

Type
Label
  • Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells (Articolo in rivista) (literal)
Anno
  • 2012-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1371/journal.pone.0049193 (literal)
Alternative label
  • Zanin, Sofia; Borgo, Christian; Girardi, Cristina; O'Brien, Sean E.; Miyata, Yoshihiko; Pinna, Lorenzo A.; Donella-Deana, Arianna; Ruzzene, Maria (2012)
    Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
    in PloS one
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Zanin, Sofia; Borgo, Christian; Girardi, Cristina; O'Brien, Sean E.; Miyata, Yoshihiko; Pinna, Lorenzo A.; Donella-Deana, Arianna; Ruzzene, Maria (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url
  • http://www.ncbi.nlm.nih.gov/pubmed/23145120 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 7 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 13 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 11 (literal)
Note
  • Scopu (literal)
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1 - 3, 7: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy; 4: Cylene Pharmaceuticals, San Diego, California, United States of America; 5: Department of Cell and Developmental Biology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan; 6, 8: Department of Biomedical Sciences and National Research Council Institute of Neurosciences, University of Padova, Padova, Italy / Venetian Institute of Molecular Medicine, Padova, Italy (literal)
Titolo
  • Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells (literal)
Abstract
  • CK2 is a pleiotropic protein kinase, which regulates many survival pathways and plays a global anti-apoptotic function. It is highly expressed in tumor cells, and is presently considered a promising therapeutic target. Among the many inhibitors available for this kinase, the recently developed CX-4945 and CX-5011 have proved to be very potent, selective and effective in inducing cell death in tumor cells; CX-4945 has recently entered clinical trials. However, no data are available on the efficacy of these compounds to overcome drug resistance, a major reasons of cancer therapy failure. Here we address this point, by studying their effects in several tumor cell lines, each available as variant R resistant to drug-induced apoptosis, and normal-sensitive variant S. We found that the inhibition of endogenous CK2 was very similar in S and R treated cells, with more than 50% CK2 activity reduction at sub-micromolar concentrations of CX-4945 and CX-5011. A consequent apoptotic response was induced both in S and R variants of each pairs. Moreover, the combined treatment of CX-4945 plus vinblastine was able to sensitize to vinblastine R cells that are otherwise almost insensitive to this conventional antitumor drug. Consistently, doxorubicin accumulation in multidrug resistant (MDR) cells was greatly increased by CX-4945. In summary, we demonstrated that all the R variants are sensitive to CX-4945 and CX-5011; since some of the treated R lines express the extrusion pump Pgp, often responsible of the MDR phenotype, we can also conclude that the two inhibitors can successfully overcome the MDR phenomenon. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it